Bispecific development is advancing.
But the path to differentiation is getting harder.
For bispecific developers, the challenge is no longer identifying promising biology. Its understanding which opportunities can translate into differentiated, clinically viable and commercially valuable therapies.
Our Review helps answer the questions that matter most:
- Where is the pipeline growing? Track the latest activity across bispecifics, T-cell engagers, multispecific formats and novel mechanisms.
- Which programs are progressing? Monitor clinical progression, approvals, discontinuations, and late-stage assets.
- Where is competition intensifying? Benchmark target combinations, mechanisms, structural formats, and leading developers.
- What is attracting investment? Analyze deal activity, strategic transactions, and emerging areas of commercial interest.
- Where is innovation moving next? Explore the rise of bispecific ADCs, trispecifics, and other emerging architectures.
What’s Inside?
The Drug Landscape
Understand how the bispecific pipeline has expanded to 3.8k+ assets, including emerging formats, target combinations, mechanisms of action, and the continued growth of bispecific ADCs and higher-order multispecifics.
The Trial Landscape
Track activity across 3.9k clinical trials, including trial initiations, status changes, combination therapy trends, geographic hotspots, and key clinical milestones shaping the field.
The Commercial Landscape
Explore the partnering, licensing, financing, and M&A activity driving the market, and uncover how investment priorities are evolving in an increasingly selective bispecific ecosystem.
Regulatory Announcements
Monitor the approvals, IND/CTA activity, designations, and regulatory milestones advancing the next generation of bispecific therapies into clinical development and commercialization.
Patent Landscape
Analyze 4.5k patent family publications to identify emerging areas of innovation, leading assignees, competitive IP strategies, and growing investment in bispecific ADCs and complex multispecific formats.
The Future of Bispecifics
Discover how clinical progression, regulatory momentum, novel mechanisms, and differentiated architectures are shaping the future of multispecific antibody development.
Previous Bispecific Landscape Reviews
Bispecific 2025 Landscape Review
Bispecific H1 2025 Landscape Review
Bispecific 2024 Landscape Review
You May Also Be Interested In…
Learn More About Bispecific
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
